January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
January 2025 in “International Journal of Dermatology Sciences” Nail changes in alopecia areata are common and may indicate severity and genetic risk.
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata might help slow down certain cancers.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.
January 2024 in “Frontiers in endocrinology” The study suggests that hypothyroidism may cause alopecia areata.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
October 2023 in “Benha Journal of Applied Sciences” PPAR-γ may be a key target for treating alopecia areata and other skin conditions.
September 2023 in “Medical and Clinical Case Reports” People with Alopecia Areata often have thyroid problems like Hashimoto thyroiditis and hypothyroidism.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
July 2023 in “Research Square (Research Square)” Certain gut bacteria may protect against alopecia areata, while others may increase the risk.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
January 2023 in “Annals of Dermatology” Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.
December 2022 in “Rossijskij žurnal kožnyh i veneričeskih boleznej” New treatments for child hair loss due to immune issues are effective but not yet officially approved.
October 2022 in “The Egyptian Journal of Hospital Medicine” Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.
August 2022 in “Revista de la Universidad Industrial de Santander/Salud UIS” Stress-related hair loss was reversed with a special medication.
July 2021 in “International journal of homoeopathic sciences” Homeopathic treatment can help manage alopecia areata in children.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
January 2021 in “Online Publication Service of Würzburg University (Würzburg University)” Diphenylcyclopropenon treatment for Alopecia areata is effective and safe, improving patients' quality of life.
March 2014 in “Journal of the American Academy of Dermatology” Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.
16 citations
,
May 2011 in “Dermatologic therapy” Effective treatments for severe alopecia areata are still lacking.
July 2018 in “Our Dermatology Online” Alopecia areata does not affect areas with psoriasis plaques.
January 2023 in “Research Square (Research Square)” Blacks and Hispanics have higher chances of alopecia areata than Whites.
41 citations
,
September 2018 in “Australasian journal of dermatology” No systemic treatment for alopecia areata has strong evidence of effectiveness.
40 citations
,
April 2013 in “Dermato-endocrinology” People with chronic Alopecia Areata often have lower vitamin D levels.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.